Lupin and Amman Pharma sign licensing agreement for Ranibizumab biosimilar
Ranibizumab is used in the treatment of various age related eye conditions.
Source: moneycontrol.com
Amman Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Amman Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Amman Pharma Today - Breaking & Trending Today
Lupin ties up with Amman Pharma for commercialisation of biosimilar product
Lupin has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries including Saudi Arabia, UAE, Iraq and Lebanon.
Source: indiatimes.com
Lupin : November 10, 2023 Lupin and Amman Pharma Sign Exclusive Licensing and Supply Agreement for Ranibizumab Biosimilar -November 10, 2023 at 04:39 pm EST
Pioneering access to this complex ophthalmic biosimilar medicine in the MENA Region Mumbai, Jordan, November 10, 2023: Global Pharma major Lupin Limited has...
Source: marketscreener.com
Insights on the Eye Drops Industry in Saudi Arabia to 2027
Dublin, June 02, 2022 (GLOBE NEWSWIRE) -- The "Saudi Arabia Eye Drops Market, By Type (Prescription v/s Over-The-Counter), By Drug Class (Antiallergy,...
Source: globenewswire.com